121104-96-9
基本信息
化合物 T10755L
CELGOSIVIR, Α-葡萄糖苷酶抑制剂
MX3253
MBI 3253
MDL 28574
celgosivir
Celgosivir (free base)
6-O-butyl castanospermine
6-Butyryl castanospermine
Castanospermine 6-butyrate
MDL28574
MDL-28574
MDL 28574
物理化学性质
| 熔点 | 114-115 °C |
| 沸点 | 422.9±45.0 °C(Predicted) |
| 密度 | 1.33±0.1 g/cm3(Predicted) |
| 储存条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | Chloroform (Slightly), DMSO (Slightly) |
| 酸度系数(pKa) | 13.14±0.70(Predicted) |
| 形态 | Solid |
| 颜色 | White to Pale Beige |
| 水溶解性 | H2O: 2mg/mL, clear |
| 稳定性 | Hygroscopic |
| InChI | 1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m0/s1 |
| InChIKey | HTJGLYIJVSDQAE-VWNXEWBOSA-N |
| SMILES | O[C@@H]1[C@@H](OC(CCC)=O)CN2[C@@]([C@@H](O)CC2)([H])[C@H]1O |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| WGK Germany | WGK 3 |
| 存储类别 | 11 - Combustible Solids |
CELGOSIVIR价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-16134 | CELGOSIVIR Celgosivir | 121104-96-9 | 5 mg | 1700元 |
| 2026/09/15 | HY-16134 | CELGOSIVIR Celgosivir | 121104-96-9 | 10 mg | 2750元 |
| 2026/09/15 | HY-16134 | CELGOSIVIR Celgosivir | 121104-96-9 | 25 mg | 5800元 |
常见问题列表
IC50: 1.27 μM (α-glucosidase I)
Celgosivir is more effective (IC 50 =20 μM) than the parent molecule (IC 50 =254 μM) at causing the accumulation of glucosylated oligosaccharides in HIV-infected cells by inhibition of glycoprotein processing. Celgosivir exhibits potent antiviral activity against HIV-1 with an IC 50 of 2.0±2.3 μM. Bovine viral diarrhoea virus (BVDV) is a closely related virus of hepatitis C virus (HCV). Celgosivir inhibits BVDV with IC 50 values of 16 and 47 μM in plaque assay and cytopathic effect assay, respectively. Celgosivir inhibits DENV2 replication with an EC 50 of 0.2 μM. The EC 50 values against DENV1, 3 and 4 are less than 0.7 μM.
Celgosivir fully protects AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50 mg/kg twice daily (BID) for 5 days and is effective even after 48 h delayed treatment. The protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10 mg/kg is more protective than a single daily dose of 100 mg/kg. Pharmacokinetics studies of celgosivir in mice shows that it rapidly metabolizes to castanospermine. During primary infection with a mouse-adapted DENV strain S221, mice shows increased viremia on day 3, yet 80% survived day 10 with virus completely cleared by day 8.